30.44

0.43% -0.13

Castle Biosciences Inc (CSTL)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt CSTL? Forum Prognose

Schlusskurs vom Vortag:

$30.57

Offen:

$30.84

24-Stunden-Volumen:

136.99K

Relative Volume:

0.36

Marktkapitalisierung:

$856.18M

Einnahmen:

$219.79M

Nettoeinkommen (Verlust:

$-57.47M

KGV:

-9.0866

EPS:

-3.35

Netto-Cashflow:

$-19.25M

1W Leistung:

+6.99%

1M Leistung:

-2.96%

6M Leistung:

+24.91%

1J Leistung:

+53.89%

1-Tages-Spanne:

$30.28

$31.19

1-Wochen-Bereich:

$28.38

$31.23

52-Wochen-Spanne:

$16.96

$35.84

Castle Biosciences Inc Stock (CSTL) Company Profile

Firmenname

Castle Biosciences Inc

Sektor

Healthcare (1200)

Branche

Diagnostics & Research (57)

Telefon

866-788-9007

Adresse

505 S FRIENDSWOOD DRIVE, FRIENDSWOOD, TX

Mitarbeiter

710

Twitter

@castlebio

Nächster Verdiensttermin

2024-11-04

Neueste SEC-Einreichungen

CSTL's Discussions on Twitter

Vergleichen Sie CSTL mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
CSTL Castle Biosciences Inc	30.44	856.18M	219.79M	-57.47M	-19.25M	-3.35
TMO Thermo Fisher Scientific Inc	521.66	199.82B	42.37B	6.14B	7.78B	15.26
DHR Danaher Corp	238.83	173.66B	23.74B	3.89B	4.98B	7.93
A Agilent Technologies Inc	138.14	38.64B	6.51B	1.29B	1.37B	3.82
IQV Iqvia Holdings Inc	201.43	36.52B	15.32B	1.41B	1.96B	5.95
IDXX Idexx Laboratories Inc	421.76	34.55B	3.84B	866.24M	792.60M	9.80

Castle Biosciences Inc Stock (CSTL) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2023-12-14	Eingeleitet	Guggenheim	Buy
2023-01-05	Eingeleitet	Scotiabank	Sector Outperform
2022-01-07	Eingeleitet	Stephens	Overweight
2021-04-30	Eingeleitet	Lake Street	Buy
2020-11-10	Eingeleitet	KeyBanc Capital Markets	Overweight
2019-12-27	Bestätigt	Canaccord Genuity	Buy
2019-08-19	Eingeleitet	BTIG Research	Buy
2019-08-19	Eingeleitet	Canaccord Genuity	Buy
2019-08-19	Eingeleitet	Robert W. Baird	Outperform
2019-08-19	Eingeleitet	SVB Leerink	Outperform

Alle ansehen

Castle Biosciences Inc Aktie (CSTL) Neueste Nachrichten

Nov 27, 2024

43,894 Shares in Castle Biosciences, Inc. (NASDAQ:CSTL) Acquired by Dynamic Technology Lab Private Ltd - MarketBeat

Nov 27, 2024

Nov 24, 2024

Connor Clark & Lunn Investment Management Ltd. Grows Stock Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) - MarketBeat

Nov 24, 2024

Nov 22, 2024

Gene Panel Market to Surpass USD 11.75 Billion by 2031 | SkyQuest Technology - GlobeNewswire Inc.

Nov 22, 2024

Nov 20, 2024

Castle Biosciences to Present at the Piper Sandler 36th Annual Healthcare Conference - BioSpace

Nov 20, 2024

Castle Biosciences to Present at Piper Sandler Healthcare Conference in December | CSTL Stock News - StockTitan

Nov 20, 2024

Castle Biosciences (CSTL) Upgraded to Strong Buy: Here's Why - MSN

Nov 20, 2024

Nov 19, 2024

Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fourth Consecutive Year - Business Wire

Nov 19, 2024

Nov 15, 2024

Castle Biosciences (NASDAQ:CSTL) Shares Down 7.3% Following Insider Selling - MarketBeat

Nov 15, 2024

Nov 14, 2024

Castle Biosciences CEO Derek Maetzold sells $175,087 in stock - Investing.com

Nov 14, 2024

GSA Capital Partners LLP Takes $1.48 Million Position in Castle Biosciences, Inc. (NASDAQ:CSTL) - MarketBeat

Nov 14, 2024

Nov 13, 2024

WASATCH ADVISORS LP's Strategic Reduction in Castle Biosciences Inc Holdings - GuruFocus.com

Nov 13, 2024

Nov 12, 2024

Castle Biosciences' (NASDAQ:CSTL) Performance Is Even Better Than Its Earnings Suggest - Yahoo Finance

Nov 12, 2024

Nov 11, 2024

Castle Biosciences, Inc. (NASDAQ:CSTL) Shares Bought by Lisanti Capital Growth LLC - MarketBeat

Nov 11, 2024

Principal Financial Group Inc. Purchases 40,377 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) - MarketBeat

Nov 11, 2024

Nov 09, 2024

Lake Street Capital Increases Castle Biosciences (NASDAQ:CSTL) Price Target to $40.00 - Defense World

Nov 09, 2024

Castle Biosciences (CSTL) Is a Great Choice for 'Trend' Investors, Here's Why - MSN

Nov 09, 2024

Nov 08, 2024

Castle Biosciences' chief commercial officer sells $124,708 in stock - Investing.com India

Nov 08, 2024

Castle Biosciences to Present New Data Highlighting the Clinical Performance of DecisionDx®-Melanoma and MyPath® Melanoma at the American Society of Dermatopathology 61st Annual Meeting - BioSpace

Nov 08, 2024

Castle Biosciences' chief commercial officer sells $124,708 in stock By Investing.com - Investing.com Canada

Nov 08, 2024

Castle Biosciences, Inc. (NASDAQ:CSTL) Given Average Recommendation of "Buy" by Analysts - MarketBeat

Nov 08, 2024

Nov 07, 2024

Kornitzer Capital Management Inc. KS Sells 135,636 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) - MarketBeat

Nov 07, 2024

Castle Biosciences Surpasses 25,000 Test Reports Delivered for its TissueCypher® Barrett’s Esophagus Test - The Bakersfield Californian

Nov 07, 2024

Nov 06, 2024

Castle Biosciences CEO Derek Maetzold sells shares worth $166,819 By Investing.com - Investing.com UK

Nov 06, 2024

Use of Castle Biosciences’ DecisionDx®-Melanoma Test Significantly Reduces Unnecessary SLNB Procedures, Latest Findings from Prospective, Multicenter DECIDE Study Presented at Dermato-Onco2024 - BioSpace

Nov 06, 2024

Castle Biosciences price target raised to $39 from $37 at Baird - Yahoo Finance

Nov 06, 2024

Castle Biosciences Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Nov 06, 2024

Castle Biosciences price target raised to $36 from $28 at KeyBanc - Yahoo Finance

Nov 06, 2024

Castle Biosciences director Daniel Bradbury sells $273,251 in stock - Investing.com

Nov 06, 2024

Castle Biosciences' chief commercial officer sells $109,709 in stock - Investing.com

Nov 06, 2024

Nov 05, 2024

Castle Biosciences director Daniel Bradbury sells $273,251 in stock By Investing.com - Investing.com UK

Nov 05, 2024